Table 3.

Matrigel promoted teratoma formation of iPSCs delivered into the body cavity.

iPSC type	Recipient animal	Route of administration	Dose	Frequency of administration	Matrigel	Disease model	Time of observation	Number of animals	Rate of teratoma formation
C57BL/6-1	Male, C57BL/6	Topically smeared on wound surface	1×105	Single	No, but in 15 μL PBS	Excisional skin wound	180 days	30	0%
C57BL/6-1	Male, C57BL/6	Topically smeared on wound surface	1×105	Single	No, but in 15 μL PBS	Excisional skin wound in streptozotocin-induced insulitis and diabetic mice	180 days	30	0%
C57BL/6-1	Male, C57BL/6	Topically smeared on Pancreas	1×106	Single	No, but in 200 μL low melting point agarose	Streptozotocin-induced insulitis and diabetes	180 days	30	0%
C57BL/6-2	Male, C57BL/6	Beneath kidney capsule	1×106	Single	No, but in 100 μL PBS	None	180 days	30	0%
C57BL/6-2	Male, C57BL/6	Beneath kidney capsule	1×106	Single	Yes, 100 μL	None	28 days	10	100%
C57BL/6-2	Male, C57BL/6	Intraperitoneally	5×106	Single	No, but in 200 μL PBS	None	180 days	20	0%
C57BL/6-2	Male, C57BL/6	Intraperitoneally	5×106	Single	No, but in 200 μL PBS	None	18 months	10	0%
C57BL/6-1	Male, C57BL/6	Intraperitoneally	5×106	Single	Yes, 200 μL	None	28 days	10	60%
C57BL/6-2	Male, C57BL/6	Intrapleurally	5×106	Single	No, but in 200 μL PBS	None	180 days	20	0%
C57BL/6-2	Male, C57BL/6	Intrapleurally	5×106	Single	No, but in 200 μL PBS	None	18 months	10	0%
C57BL/6-2	Male, C57BL/6	Intrapleurally	5×106	Single	Yes, 200 μL	None	180 days	10	0%